Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: From the 10Q - subsequent events

Oct 24, 2006 07:57AM
Thanks for posting note 6. It may be great to end the anti-dilution clause, but once again ultimate control has been placed in hands of S/L. Looks like plan of aquisition by issue of shares in mind. The new company must bring very positive revs/growth that Far outweighs the large dilution.
Share
New Message
Please login to post a reply